Revolution Medicines Inc. 美股招股说明书（2026-02-25版）

PROSPECTUS SUPPLEMENT(To prospectus dated March4, 2024) Up to $1,000,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC (“TD Cowen”) relating to shares of our common stock offered by thisprospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of ourcommon stock, $0.0001 par value per share, having an aggregate offering price of up to $1.0billion from time to time through or to TD Cowen acting as Our common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.” On February19, 2026, the last reported sale price of ourcommon stock on the Nasdaq Global Select Market was $102.74 per share. Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus will be made in negotiated transactions,including block trades or block sales, or by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgatedunder the Securities Act of 1933, as amended (the “Securities Act”), including without limitation sales made through the Nasdaq Global Select Marketor on any other trading market for our common stock or by any other method permitted by law. TD Cowen is not required to sell any specific amount of The compensation to TD Cowen for sales of shares of common stock sold pursuant to the sales agreement will be an amount up to 3.0% of the grossproceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, TD Cowen willbe deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of TD Cowen will be deemed to be underwriting Our business and an investment in our common stock involve significant risks. These risks are described under thecaption “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents incorporated byreference into this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passedupon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminaloffense. February 25, 2026 Table of Contents TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENTMARKET, INDUSTRY AND OTHER DATA PROSPECTUS SUPPLEMENT SUMMARYRISK FACTORS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS ABOUT THIS PROSPECTUSWHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCEABOUT THE COMPANY Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the “SEC”), utilizing a“shelf” registration process. By using an automatic shelf registration statement, we may sell an unspecified amount of securities from time to time.Under this prospectus supplement, we may offer shares of our common stock having an aggregate offering price of up to $1.0billion from time to time We provide information to you about this offering of shares of our common stock in two separate documents that are bound together: (1)this prospectussupplement, which describes the specific details regarding this offering; and (2)the accompanying prospectus, which provides general information,some of which may not apply to this offering. Generally, when we refer to this “prospectus,” we are referring to both documents combined. Ifinformation in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. However, ifany statement in one of these documents is inconsistent with a statement in another document having a later date—for example, a document We have not, and TD Cowen has not, authorized anyone to provide any information other than that contained in or incorporated by reference in thisprospectus supplement, the accompanying prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you.We and TD Cowen take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Weare not, and TD Cowen is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is notauthorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer orsolicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporatedby reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdicti